All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2021-03-22T14:32:57.000Z

Phase III trial of entospletinib is first to evaluate MRD-negative CR as primary endpoint in AML setting

Mar 22, 2021
Share:

Bookmark this article

A phase III trial investigating the safety and efficacy of entospletinib for the treatment of patients with newly diagnosed NPM1-mutated acute myeloid leukemia (AML) has been initiated. This trial represents the first in the AML setting to evaluate measurable residual disease (MRD)-negative complete remission (CR) as a primary endpoint.

The trial will recruit approximately 180 adult patients, who will be randomized to receive ≥2 cycles of either entospletinib or placebo, plus conventional induction and consolidation chemotherapy. The primary endpoint is MRD-negative CR, determined using next-generation sequencing (NGS).

Entospletinib is an inhibitor of the oncogene spleen tyrosine kinase (SYK), a key mediator of AML maintenance and progression via the elevated expression of HOXA9 and MEIS1 transcription factors. Aberrations in NPM1 and other AML driver genes have been associated with increased expression of these transcription factors.

In a phase Ib/II trial (NCT02343939), entospletinib in combination with intensive chemotherapy induced higher response rates in patients with NPM1-mutated AML (n = 15; 87%) compared with the entire patient population (n = 53; 70%), and was well tolerated.2  

The phase III trial is due to commence mid-2021 and the MRD data anticipated in 2023. For more information on the value of MRD status as a predictor of outcome in patients with NPM1-mutated AML, click here.

  1. Kronos Bio. Kronos Bio announces positive end-of-phase 2 meeting with FDA for entospletinib in newly diagnosed NPM1-mutated acute myeloid leukemia (AML). https://markets.businessinsider.com/news/stocks/kronos-bio-announces-positive-end-of-phase-2-meeting-with-fda-for-entospletinib-in-newly-diagnosed-npm1-mutated-acute-myeloid-leukemia-aml-1030149679. Published Mar 4, 2021. Accessed Mar 18, 2021.
  2. Walker A, Byrd J, Blachly J, et al. Entospletinib in combination with induction chemotherapy in previously untreated acute myeloid leukemia: response and predictive significance of HOXA9 and MEIS1 expression. Clin Cancer Res. 2020;26(22):5852-5859. DOI: 1158/1078-0432.CCR-20-1064

Your opinion matters

Do you intend to implement next generation sequencing for measurable residual disease monitoring in AML patients?
0 votes - 5 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox